Efficacy comparison of 3 rivaroxaban regimen in patients with venous thromboembolism
10.3760/cma.j.issn.0253-3758.2015.09.007
- VernacularTitle:利伐沙班治疗静脉血栓栓塞症的初步临床观察
- Author:
Qin ZHOU
1
;
Yan WU
;
Xin JIANG
;
Xinglan LIU
;
Han LEI
;
Zhicheng JING
;
Wei HUANG
Author Information
1. 400016,重庆医科大学附属第一医院心血管内科
- Keywords:
Thromboembolism;
Pulmonary embolism;
Anticoagulants
- From:
Chinese Journal of Cardiology
2015;43(9):782-784
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of 3 rivaroxaban regimen in patients with venous thromboembolism (VTE).Methods This is a retrospective study.Thirty three inpatients with VTE received rivaroxaban were divided into 3 groups,in which 16 patients were treated with 15 mg rivaroxaban twice daily for 21 days then followed by 20 mg once per day till 3 months (group 1),9 patients were treated with 20 mg rivaroxaban once daily for 3 months (group 2),8 patients were treated with 10 mg rivaroxaban once daily for 3 months.The reduction rate of D-Dimer on the third therapy day,the duration of D-Dimer normalization and hospital stay as well as symptom remission,the imaging assessment results after three months treatment,rate of recurrent VTE,bleeding,liver and kidney function were compared among the 3 groups.Results The reduction rates of D-Dimer on the third therapy day were significantly higher ((46.12±15.42)％ vs.(26.59±8.11)％ and(25.55 ± 14.00)％,P =0.02,P=0.01),and the duration of D-Dimer normalization was significantly shorter ((17.9 ±7.7) days vs.(24.1 ±5.1) days and (26.3 ± 6.2) d,P =0.03,P ＜ 0.01) in group 1 than in group 2 and 3.There was one recurrent deep-vein thrombosis in group 3,one non-major bleeding in group 1 and group 3.Major bleeding or liver and kidney dysfunction were not observed in these patients.Conclusions Venous thromboembolism can be safely and effectively treated by rivaroxaban,and does of 15 mg twice daily for 21 days followed by 20 mg once daily for 3 months are superior to the other 2 tested therapy regimen in this patient cohort.
